SIONNA THERAPEUTICS INC (SION) competitors & alternatives
Health Care · NASDAQ
SIONNA THERAPEUTICS INC (SION)'s top competitors and alternatives — its most similar public companies — include Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Insmed (INSM), NURIX THERAPEUTICS INC (NRIX), Neurocrine Biosciences (NBIX), HARMONY BIOSCIENCES HLDG INC (HRMY), KURA ONCOLOGY INC (KURA), SOLID BIOSCIENCES INC (SLDB), RELMADA THERAPEUTICS INC (RLMD), PROTHENA PLC (PRTA), AGENUS INC (AGEN) and VOYAGER THERAPEUTICS INC (VYGR). These are SIONNA THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top SION competitors & alternatives
-
Vertex PharmaceuticalsVRTXHealth Care
Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and…
$472.57 (as of 2026-07-22) · market cap $121.4B
-
AbbVieABBVHealth Care
Global biopharmaceutical company with leadership positions in immunology, neuroscience, oncology, and aesthetics targeting complex diseases.
$253.30 (as of 2026-07-22) · market cap $452.5B
-
InsmedINSMHealth Care
A biopharmaceutical company with approved rare respiratory therapies (ARIKAYCE for MAC lung disease, BRINSUPRI for bronchiectasis) and a pipeline in…
$106.64 (as of 2026-07-22) · market cap $23.4B
-
NURIX THERAPEUTICS INCNRIXHealth Care
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate…
$23.60 (as of 2026-07-22) · market cap $2.4B
-
Neurocrine BiosciencesNBIXHealth Care
Neurocrine is a profitably growing, neuroscience-focused biotech commercializing novel treatments for movement disorders, endocrine diseases, and psychiatric…
$172.69 (as of 2026-07-22) · market cap $17.8B
-
HARMONY BIOSCIENCES HLDG INCHRMYHealth Care
Harmony Biosciences is a neuroscience-focused biopharmaceutical company commercializing WAKIX (pitolisant), the first-in-class non-controlled H3 receptor…
$34.86 (as of 2026-07-22) · market cap $2.0B
-
KURA ONCOLOGY INCKURAHealth Care
Clinical-stage oncology company commercializing KOMZIFTI for cancer and advancing a pipeline of targeted therapeutics through strategic partnerships.
$10.54 (as of 2026-07-22) · market cap $944M
-
SOLID BIOSCIENCES INCSLDBHealth Care
A gene therapy company advancing a pipeline of treatments for rare neuromuscular and cardiac diseases including Duchenne muscular dystrophy, Friedreich's…
$8.10 (as of 2026-07-22) · market cap $808M
-
RELMADA THERAPEUTICS INCRLMDHealth Care
Clinical-stage biotech redirecting toward oncology and neurology with in-licensed chemotherapy delivery and neurosteroid platforms after terminating its lead…
$5.00 (as of 2026-07-22) · market cap $524M
-
PROTHENA PLCPRTAHealth Care
A clinical-stage biotech developing antibody therapies targeting misfolded proteins in Parkinson's disease, Alzheimer's disease, and rare amyloidosis through…
$8.44 (as of 2026-07-22) · market cap $458M
-
AGENUS INCAGENHealth Care
A clinical-stage immuno-oncology company advancing checkpoint immunotherapy and combination therapies, primarily botensilimab, while generating near-term…
$5.53 (as of 2026-07-22) · market cap $232M
-
VOYAGER THERAPEUTICS INCVYGRHealth Care
A gene therapy company developing AAV-based therapeutics and non-viral treatments for neurological diseases, relying heavily on partnership revenue while…
$3.10 (as of 2026-07-22) · market cap $187M
Not quite? Describe exactly what you want →
Peers are SIONNA THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: SIONNA THERAPEUTICS INC (SION).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.